Combined Afirma Genomic Sequencing Classifier and <i>TERT</i> promoter mutation detection in molecular assessment of Bethesda III–VI thyroid nodules-Reference-Cited by-同舟云学术

Combined Afirma Genomic Sequencing Classifier and TERT promoter mutation detection in molecular assessment of Bethesda III–VI thyroid nodules

Published:2023-08-06 Issue:10 Volume:131 Page:609-613
ISSN:1934-662X
Container-title:Cancer Cytopathology
language:en
Short-container-title:Cancer Cytopathology

Author:

Ladenson Paul W.¹,Klopper Joshua P.²,Hao Yangyang³,Kaushik Praveen⁴,Walsh P. Sean³,Huang Jing³,Kloos Richard T.²^ORCID,Ali Syed Z.⁵

Affiliation:

1. Division of Endocrinology, Diabetes, and Metabolism Department of Medicine The Johns Hopkins University School of Medicine Baltimore Maryland USA

2. Department of Medical Affairs Veracyte South San Francisco California USA

3. Department of Research and Development Veracyte South San Francisco California USA

4. Department of Marketing Veracyte South San Francisco California USA

5. Department of Pathology The Johns Hopkins University School of Medicine Baltimore Maryland USA

Abstract

Molecular analysis of thyroid nodules can provide diagnostic and prognostic information as well as indicate opportunities for targeted therapy. Whole RNA exome analysis offers information that can be leveraged to predict tumor behavior.

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference33 articles.

1. The 2017 Bethesda System for Reporting Thyroid Cytopathology

2. Preoperative Diagnosis of Benign Thyroid Nodules with Indeterminate Cytology

3. Performance of a Genomic Sequencing Classifier for the Preoperative Diagnosis of Cytologically Indeterminate Thyroid Nodules

4. Maximizing Small Biopsy Patient Samples: Unified RNA-Seq Platform Assessment of over 120,000 Patient Biopsies

5. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer